.jpeg)
{{ variable.name }}
Bituvir is a compound antiviral preparation, containing the integrase inhibitor bictegravir (BIC), the nucleoside reverse transcriptase inhibitor emtricitabine (FTC) and tenofovir alafenamide (TAF).
1. Common name : Bictegravir/Emtricitabine/Tenofoviralafenamide (Bictegravir/Emtricitabine/Tenofoviralafenamide)
2. Trade name u20 0c:Biktarvy®
3. Dosage form :Film-coated tablets
4. Main ingredients :Each tablet contains bictegravir sodium 52.5mg (equivalent to bictegravir 50mg), emtricitabine 200mg, and tenofovir alafenamide 28mg (equivalent to tenofovir 25mg). Excipients include croscarmellose sodium, magnesium stearate, etc.
HIV-1 infection : is used to treat HIV-1 infection in adults and is suitable for the following two types of patients:
< p>Patients who have not received antiretroviral treatment;Patients who are virologically suppressed (HIV-1RNA<50 copies/mL) and have no history of treatment failure can replace the current stable regimen (need to continue taking medication for ≥3 months).
1. Specifications of : Each tablet contains 50 mg of bictegravir, 200 mg of emtricitabine, and 25 mg of tenofovir.
2. Characteristics : Capsule-shaped film-coated tablets.
1. Recommended dosage of : Take 1 tablet per day, orally, with food or on an empty stomach.
2. Treatment of missed doses : If you miss a dose, take it as soon as possible; if it is close to the next dose time (within 4 hours), skip the missed dose.
3. Vomiting treatment : If you vomit after taking the medicine, there is no need to take a supplement. Take the next medicine as originally planned.
1. Renal insufficiency : It is not recommended for those with creatinine clearance (CrCl) <30mL/min.
2. Hepatic insufficiency : Contraindicated in patients with Child-Pugh class C (severe).
1. Influence of diet : is not affected by food, but avoid taking it with antacids containing aluminum/magnesium/calcium (an interval of 2 hours is required).
2. HBV co-infection : The risk of hepatitis recurrence needs to be monitored after discontinuation of treatment.
3. Drug interaction : It is prohibited to use digoxin and rifampicin together.
1. U200c for pregnant women: The pros and cons need to be weighed, and medication during pregnancy needs to be registered (APR registration number 1-800-258-4263).
2. Lactation : Breastfeeding is prohibited.
3. Children : Safety for children under 18 years of age has not been established.
1. Common (≥5%) : Diarrhea (6%), nausea (5%), headache (5%).
2. Severe reactions : Immune reconstitution syndrome (5.3%), lactic acidosis (rare).
1. Those who take digoxin or rifampicin in combination;
2. Those who are allergic to the ingredients.
1. Strong CYP3A inducer (such as rifampin): reduces the concentration of bictegravir and is prohibited from combined use;
2. OCT2/MATE1 substrate (such as metformin): may increase its plasma concentration.
1. Store in original packaging, moisture-proof, with built-in desiccant;
2. Store in original packaging, moisture-proof, with built-in desiccant; Storage temperature: <30°C.
Note : Renal function, HBV markers and HIV viral load need to be monitored regularly during treatment. There is no need to take a missed dose or after vomiting, but the daily dosing schedule must be strictly followed.